GlassScriptPhysician profile
Alla Goldberg
NPI 1467698480
$2,944.17
in general payments reported to CMS, 2019-2025
19 companies · $57.60 in 2025
The $57.60 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $358 · 2021: $435 · 2022: $810 · 2023: $246 · 2024: $361 · 2025: $57.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $532.74 | 2019-2024 | Tavneos, Parsabiv, Epogen |
| Vifor Pharma, INC. | $420.24 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $405.71 | 2019-2024 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $338.73 | 2019-2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $153.60 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $149.30 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $140.78 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $136.94 | 2019-2022 | |
| Travere Therapeutics, INC. | $107.65 | 2019-2023 | |
| Akebia Therapeutics INC | $94.63 | 2020-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $86.61 | 2022-2023 | |
| Daiichi Sankyo INC. | $74.77 | 2019-2020 | |
| Horizon Therapeutics Plc | $66.57 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $62.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.84 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $44.57 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.85 | 2021 | |
| Lilly USA, LLC | $26.10 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $22.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.